The Nottingham, UK-based firm has completed a £1.5m ($2m) expansion to a larger, self-contained facility in order to increase its offering to include a range of new production services.
According to CEO Richard Johnson, the expansion was both driven by demand from clients and a strategic necessity for the company.
“We realise as a business that we need to offer this service to our customers in order to support continued growth,” he told this publication.
The 15,000 sq ft facility will house R&D, quality assurance and manufacturing departments, with the latter planned to be MHRA validated for clinical trials manufacturing by the third quarter this year.
It will also focus on dry powder formulations for capsules, tablets (oral dosage forms) and pulmonary and nasal devices, he said, focused on Phase I and II clinical trial supply.
Core equipment will be a Niro PSD-1 and ProCePT scale spray dryers with associated powder handling and dosage form development capabilities, with the larger spray dryer able to make batch sizes of several kilograms of spray dried powder.